– Glooko, a global digital health company, has announced a successful Series F funding round, raising $100M to fuel its continued growth and product development led by Georgian, with participation from Health Catalyst Capital, Canaan, and other investors.
– In addition to this significant investment, Glooko also announced the appointment of Mike Alvarez as its new Chief Executive Officer.
Funding to Drive Product Innovation and Global Expansion
This substantial investment will support Glooko’s efforts to expand its digital health platform and enhance its offerings in several key areas:
- Expert Data Insights: Developing advanced analytics and reporting capabilities to provide valuable insights for patients, providers, and researchers.
- Device Integrations: Expanding the platform’s compatibility with various medical devices and wearables to streamline data collection and improve patient monitoring.
- Clinical Research: Supporting clinical trials and research initiatives through the platform’s robust data management and analytics capabilities.
- Chronic Condition Support: Enhancing features and resources to help individuals with chronic conditions, particularly diabetes, better manage their health.
Glooko Appoints Mike Alvarez as Chief Executive Officer
Mike Alvarez brings over 20 years of leadership experience in the medical device and biotechnology industries to his role as CEO of Glooko. His previous roles include serving as CEO of Qardio, a remote patient monitoring company, and holding leadership positions at Medtronic, St. Jude Medical (acquired by Abbott), and Sanofi. Alvarez’s expertise in global healthcare markets and his passion for digital health solutions make him well-suited to lead Glooko’s next phase of growth.
“The healthcare industry is currently navigating significant challenges related to data burden and clinical workflows, particularly for physicians working with patients to manage chronic conditions,” said Mr. Alvarez. “By unifying data from multiple devices onto one standardized platform, we can simplify decision-making and empower providers to translate vast amounts of data into meaningful insights. This enables timely interventions and helps create new clinical care pathways that can enhance patient outcomes. I am thrilled to join Glooko at this pivotal moment in its journey. I look forward to continued commercial acceleration as we leverage real-world data to transform chronic condition management and improve enrollment and management in clinical trials through diverse and inclusive populations.”
